Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial

The Lancet Respiratory Medicine

Volumn 4, Issue 10, 2016, Pages 797-806

  O'Byrne, Paul M ^a   Metev, Hristo ^b   Puu, Margareta ^c   Richter, Kai ^c   Keen, Christina ^c   Uddin, Mohib ^c   Larsson, Bengt ^c   Cullberg, Marie ^c   Nair, Parameswaran ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b SHATPPD Ruse EOOD   (Bulgaria)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; N [2 (2,3 DIFLUOROBENZYLTHIO) 6 (2,3 DIHYDROXY 1 METHYLPROPOXY) 4 PYRIMIDINYL] 1 AZETIDINESULFONAMIDE; PLACEBO; ANTIASTHMATIC AGENT; N-(2-(2,3-DIFLUORO-6-BENZYLTHIO)-6-(3,4-DIHYDROXYBUTAN-2-YLOXY)PYRIMIDIN-4-YL)AZETIDINE-1-SULFONAMIDE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; ASTHMA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT PLANNING; UNCONTROLLED PERSISTENT ASTHMA; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGITIS; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84989916843     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30227-2     Document Type: Article

References (30)

1. 1 Pavord, ID, Brightling, CE, Woltmann, G, Wardlaw, AJ, Non-eosinophilic corticosteroid unresponsive asthma. Lancet 353 (1999), 2213–2214.
2. 2 Berry, M, Morgan, A, Shaw, DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 62 (2007), 1043–1049.
3. 3 Busse, WW, Banks-Schlegel, S, Wenzel, SE, Pathophysiology of severe asthma. J Allergy Clin Immunol 106 (2000), 1033–1042.
4. 4 Brightling, C, Berry, M, Amrani, Y, Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 121 (2008), 5–10.
5. 5 Holgate, ST, Holloway, J, Wilson, S, et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 117 (2006), 496–506.
6. 6 Uddin, M, Nong, G, Ward, J, et al. Prosurvival activity for airway neutrophils in severe asthma. Thorax 65 (2010), 684–689.
7. 7 Nair, P, Aziz-Ur-Rehman, A, Radford, K, Therapeutic implications of ‘neutrophilic asthma’. Curr Opin Pulm Med 21 (2015), 33–38.
8. 8 Hauber, H-P, Gotfried, M, Newman, K, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 112 (2003), 58–63.
9. 9 MacDowell, AL, Peters, SP, Neutrophils in asthma. Curr Allergy Asthma Rep 7 (2007), 464–468.
10. 10 Chapman, RW, Phillips, JE, Hipkin, RW, Curran, AK, Lundell, D, Fine, JS, CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 121 (2009), 55–68.
11. 11 Gernez, Y, Tirouvanziam, R, Chanez, P, Neutrophils in chronic inflammatory airway diseases: can we target them and how?. Eur Respir J 35 (2010), 467–469.
12. 12 Chapman, RW, Minnicozzi, M, Celly, CS, et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 322 (2007), 486–493.
13. 13 Day, RB, Link, DC, Regulation of neutrophil trafficking from the bone marrow. Cell Mol Life Sci 69 (2012), 1415–1423.
14. 14 Rennard, SI, Dale, DC, Donohue, JF, et al. CXCR2 antagonist MK-7123–a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 191 (2015), 1001–1011.
15. 15 Nair, P, Gaga, M, Zervas, E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 42 (2012), 1097–1103.
16. 16 Moss, RB, Mistry, SJ, Konstan, MW, et al. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros 12 (2013), 241–248.
17. 17 De Soyza, A, Pavord, I, Elborn, JS, et al. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J 46 (2015), 1021–1032.
18. 18 Kirsten, AM, Forster, K, Radeczky, E, et al. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm Pharmacol Ther 31 (2015), 36–41.
19. 19 Jurcevic, S, Humfrey, C, Uddin, M, Warrington, S, Larsson, B, Keen, C, The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol 80 (2015), 1324–1336.
20. 20 Nicholls, DJ, Wiley, K, Dainty, I, et al. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther 353 (2015), 340–350.
21. 21 Fahy, JV, Kim, KW, Liu, J, Boushey, HA, Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 95 (1995), 843–852.
22. 22 Turner, MO, Hussack, P, Sears, MR, Dolovich, J, Hargreave, FE, Exacerbations of asthma without sputum eosinophilia. Thorax 50 (1995), 1057–1061.
23. 23 Hanania, NA, Alpan, O, Hamilos, DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 154 (2011), 573–582.
24. 24 Humbert, M, Beasley, R, Ayres, J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 (2005), 309–316.
25. 25 Vignola, AM, Humbert, M, Bousquet, J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59 (2004), 709–717.
26. 26 Wenzel, SE, Barnes, PJ, Bleecker, ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 179 (2009), 549–558.
27. 27 McCullagh, P, Nelder, JA, Generalized linear models, 2nd edn., 1989, Chapman and Hall/CRC Press, Boca Raton, FL.
28. 28 Uddin, M, Lau, LC, Seumois, G, et al. EGF-induced bronchial epithelial cells drive neutrophil chemotactic and anti-apoptotic activity in asthma. PloS One, 8, 2013, e72502.
29. 29 Kupczyk, M, Dahlén, B, Sterk, PJ, et al. Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy 69 (2014), 1198–1204.
30. 30 Zhang, XY, Simpson, JL, Powell, H, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy 44 (2014), 1137–1145.